Its also where a lot of GLP-1 journeys quietly fall apart: research suggests that roughly half of people who start these medications stop within the first year, often over side effects, cost, or simply losing touch with their prescriber
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) Wilding JPH, Batterham RL, Calanna S, et al
Weight Watchers stopped offering compounded semaglutide on May 21, 2025, after the FDA issued a warning letter to all compounding pharmacies stating that compounded semaglutide should not be dispensed and distributed unless medically necessary
The drug was already approved earlier this year for obesity and overweight with related conditions, effectively expanding the company's total addressable market with the addition of an oral alternative to injectable GLP-1 drugs.
You may find it easier to digest a capsule vs a tablet form
The GLP-1 impact is amplified by the fact that 70% of user households also change their consumer behavior
